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ORIGINAL RESEARCH
BETHANECOL CHLORIDE FOR TREATMENT OF
CLOMIPRAMINE-INDUCED ORGASMIC
DYSFUNCTION IN MALES
Márcio Bernik, Antonio Hélio Guerra Vieira and Paula Villela Nunes
BERNIK M et al. Bethanecol chloride for treatment of clomipramine-induced orgasmic dysfunction in males. Rev. Hosp.
Clin. Fac. Med. S. Paulo 59(6):357-360, 2004.
PURPOSE: To investigate whether bethanecol chloride may be an alternative for the clinical management of
clomipramine-induced orgasmic dysfunction, reported to occur in up to 96% of male users.
METHODS: In this study, 12 fully remitted panic disorder patients, complaining of severe clomipramine-induced
ejaculatory delay, were randomly assigned to either bethanecol chloride tablets (20 mg, as needed) or placebo in a randomized,
double-blind, placebo-controlled, two-period crossover study. A visual analog scale was used to assess severity of the
orgasmic dysfunction.
RESULTS: A clear improvement was observed in the active treatment period. No placebo or carry-over effects were
observed.
CONCLUSION: These findings suggest that bethanecol chloride given 45 minutes before sexual intercourse may be
useful for clomipramine-induced orgasmic dysfunction in males.
KEYWORDS: Orgasmic dysfunction. Clomipramine. Bethanecol chloride. Panic disorder. Pharmacological
treatment.
In panic disorder patients, effective
pharmacological treatment with anti-
depressants has been shown to greatly
improve the quality of life, but it is of-
ten associated with the emergence of
sexual dysfunctions.1
Sexual dysfunctions are common2-
4
 but systematically underreported side
effects.5,6 They are, nonetheless, asso-
ciated with noncompliance, leading to
early treatment dropout, treatment
nonresponse, and relapse of symp-
toms.4,7
Among the antidepressants, serot-
onin selective reuptake inhibitors
(SSRIs) and clomipramine, may cause
more sexual side effects than other
antidepressants. 6,8,9,10 Biochemical
mechanisms suggested as causative in-
clude the following: 1) increased brain
serotonin, particularly affecting 5TH2
and 5HT3 receptors; 2) decreased
dopamine; 3) central blockade of
cholinergic and alpha-1 adrenergic
receptors; 4) inhibition of nitric oxide
synthetase; 5) elevation of prolactin
levels; and 6) peripheral muscarinic
blockade.11
Clomipramine is considered the
gold standard for treatment of panic
disorder.12 On the other hand, its use
is commonly associated with sexual
side effects such as orgasmic dysfunc-
tion in up to 20% to 96% of pa-
tients.5,6,13
Clomipramine is the imipramine
analogue of chlorpromazine. Com-
pared to other tricyclic antidepressants
(TCA), it has a greater effect upon
dopamine blockade and serotonin up-
take inhibition.14 This has implications
for prolactin release15 and orgasmic
dysfunction mediated through 5HT2
receptors.16 Moreover, peripheral
antimuscarinic17 and alpha-adrenergic
blockade7,18,19 effects have also been
implicated in the mechanism of
clomipramine-induced orgasmic dys-
functions.
There are few studies of the clini-
cal management of antidepressant-in-
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duced sexual dysfunctions. Case
reposts and open trials suggested that
yohimbine,20 buproprion,21 cyprohep-
tadine,22 sildenafil citrate,10,23 bus-
pirone,6 and bethanecol chloride24-26
may be effective in antidepressant-in-
duced sexual dysfunctions.
Bethanecol chloride has mixed
central and peripheral cholinergic and
adrenergic effects. When used in doses
of 10 to 100 mg given 30 to 60 min-
utes before intercourse, it has been sug-
gested in case reports to be effective
in reversing antidepressant-induced
anorgasmia.24-26 The supposed mecha-
nism of action is the muscarinic ago-
nist-induced potentiation of adrener-
gic function.17
In this study, we further investi-
gated the efficacy of bethanecol for
the treatment of clomipramine-in-
duced orgasmic dysfunction in male
patients using clomipramine as main-
tenance treatment for panic disorder in
a randomized, double-blind, placebo-
controlled, crossover trial.
METHODS
Twelve panic disorder patients (all
male) aged 18 to 65 years gave in-
formed consent to take part in this
study. The duration of the orgasmic
dysfunction (ejaculatory delay or
anorgasmia) was 5.8 ± 5.8 (mean ±
standard deviation) months. No patient
complained of erectile dysfunction.
All patients were fully remitted
and were receiving clomipramine as
maintenance treatment. The mean
daily dose of clomipramine was 106 ±
64 mg (range: 30 - 200 mg), and the
duration of treatment was 6.9 ± 5.4
months (range: 1 - 18 months). Sub-
jects using other medications were ex-
cluded.
Inclusion criteria were absence of
sexual dysfunction prior to
clomipramine use, presence of normal
sexual desire; absence of medical ill-
ness or use of other drugs known to in-
terfere with sexual functioning; and no
personal history of asthma, coronary
insufficiency, or duodenum ulcer.
Subjects were assigned to receive
either bethanecol chloride tablets (20
mg, as needed) or placebo in a
randomized, double-blind, placebo-
controlled, two-period crossover study
(Group A = bethanecol 2 weeks/ pla-
cebo 2 weeks; Group B = placebo 2
weeks / bethanecol 2 weeks). Patients
were given either 2 capsules of 20 mg
bethanecol or 2 of placebo in each pe-
riod and were instructed to take the
medication 45 minutes before sexual
intercourse on up to 2 occasions in
each 2-week period. Additional tablets
were not provided. In order to avoid
absorption delays, subjects were in-
structed to wait 2 hours after full meals.
Patients were evaluated at baseline
and at week 2 and 4.
Baseline measures included the
Hamilton Depression Rating Scale
(HDRS27), Hamilton Anxiety Scale
(HAS28), and a visual analog sexual
function scale constructed with 6 an-
chor points (Table 1). Even though this
scale measures both erectile and ejacu-
latory (orgasmic) function, only the
orgasmic function measures were
analyzed as there were no predicted ef-
fects of both clomipramine and
bethanecol on erectile functioning.
The best scores of orgasmic func-
tion in the placebo and drug phases of
patients completing the study were
compared using a version of the
Wilcoxon rank sum test, corrected for
small samples.29 A significance level of
5% was adopted.
RESULTS
Two patients dropped out of the
study before the second period of
treatment; 1 relapsed to a depressive
episode, and the other could not adapt
his sexual habits to bethanecol chlo-
ride use. We analyzed the data on the
10 subjects who completed the study.
The baseline scores on the psycho-
pathological rating scales were HAS
(6.9 ± 3.8) and HDRS (5.7 ± 3.9). Ta-
ble 2 shows the individual scores at
baseline, placebo, and bethanecol pe-
riods. A clear improvement over base-
line was observed in the orgasmic func-
tioning of patients during the active
treatment period with bethanecol. (W
= 62; P <.025). No carry-over or pla-
cebo effects were observed.
Given the small sample size, we
could not correlate the effects of
bethanecol effects with clomipramine
dose levels or to the baseline severity
of orgasmic dysfunction.
Table 1 - Visual analog sexual function scale, anchor points.
SEXUAL FUNCTION SCALE
I) Which of the statements below best describes your erection during intercourse.
1-I had no erection.
2-I had some erection, but not enough to penetrate.
3-Loss of erection during or at the beginning of sexual intercourse.
4-Loss of the erection at the end of intercourse due to tiredness.
5-Difficulties in keeping the erection during intercourse but could finish it.
6-Normal erection, as used to be.
II) Which of the statements bellow best describes your effort to reach orgasm (ejaculation):
1-No orgasm.
2-Had an orgasm with extreme effort and tiredness.
3-Clearly needed more effort and concentration.
4-Moderate effort and more time needed to reach orgasm than normally need.
5-Noted some delay or difficulty, almost normal.
6-Usual time and effort needed to reach an orgasm.
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DISCUSSION
The small sample size imposes
limits on the generalization of the
present results. Nevertheless, we found
an improvement in the patients sexual
functioning after bethanecol. This ef-
fect was not related to psychopatho-
logical changes or clomipramine dos-
ing changes during the study. In fact,
all patients were in remission and on
maintenance doses during this trial.
The mechanism of action of
bethanecol is still not fully understood.
It has been proposed that an imbalance
between cholinergic and adrenergic
function is responsible for tricyclic anti-
depressant-induced orgasmic dysfunc-
tion.17 These authors hypothesized a
muscarinic agonist-induced potentiation
of adrenergic function as an explanation
for the effects of bethanecol. In fact yo-
himbine, an alfa-2 adrenergic antagonist,
was also shown to reverse clomipramine-
induced anorgasmia.20 More recently,
buproprion, which also promotes central
adrenergic potentiation, has also been
shown to be useful in SSRI-induced
sexual dysfunction.30 On the other hand,
mazindol, an anorectic drug that in-
creases sympathetic tonus, provokes
anorgasmia that was reversed by
bethanecol.25
We conclude that bethanecol chlo-
ride may be a valid option in the treat-
ment of clomipramine-induced orgas-
mic dysfunction.
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Table 2 - Individual data on the orgasmic functioning scale, score at baseline and
best score at each treatment period.
Patient age Clomipramine dose Baseline Placebo Bethanechol
1 44 30 mg 0 0 4
2 48 175 mg 2 2 8
3 40 75 mg 2 2 8
4 40 40 mg 2 8 8
5 43 50 mg 4 6 8
6 48 75 mg 2 4 6
7 31 200 mg 0 0 4
8 49 75 mg 2 0 4
9 65 50 mg 0 0 0
10 53 150 mg 2 2 8
RESUMO
BERNIK M e col. O uso do cloridrato
de betanecol no tratamento da
disfunção orgásmica induzida pela
clomipramina em pacientes do
sexo masculino. Rev. Hosp. Clín.
Fac. Méd. S. Paulo 59(6):357-360,
2004.
OBJETIVO: Investigar se o uso
do cloridato de betanecol é uma alter-
nativa útil no manejo clínco da dis-
função orgásmica induzida pela clomi-
pramina, relatada por até 96 % dos usu-
ários do sexo masculino.
MÉTODOS: Foram estudados 12
pacientes do sexo masculino em remis-
são completa de transtorno de pânico
porém com queixas de disfunção
orgásmica grave secundária ao uso da
clomipramina. Os pacientes foram ale-
atoriamente distribuídos ao tratamen-
to com cloridrato de betanecol (20 mg
quando necessário) ou placebo em um
estudo duplo cego “crossover” de dois
períodos.
RESULTADOS: Foi observado um
benefício claro no período de uso da
droga ativa. Não foram observados
efeito placebo ou “carry-over” nos pa-
cientes inicialmete alocados ao medi-
camento ativo.
CONCLUSÕES: Os resultados
deste estudo sugerem que o cloridato
de betanecol, usado em doses únicas,
45 minutos antes da relação sexual,
pode ser útil em pacientes do sexo
masculino apresentado disfunção
orgásmica secundária ao uso da clomi-
pramina.
UNITERMOS: Disfunção orgás-
mica. Clomipramina. Cloridrato de
betanecol. Transtorno de pânico. Tra-
tamento farmacológico.
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